Treatment of myeloma: recent developments

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Melphalan, a foundational treatment for multiple myeloma since the 1960s, initially offered limited survival benefits.
• Treatment intensification with high-dose melphalan (140-200 mg/m(2)) became necessary to improve patient outcomes.
• High-dose melphalan necessitates autologous stem cell support to mitigate severe myelosuppression.

Purpose of the Study:

• To review the evolution and current role of high-dose melphalan in multiple myeloma treatment.
• To discuss the indications for high-dose therapy and the potential benefits of further intensification (e.g., tandem or allogeneic transplantation).
• To explore emerging therapeutic modalities for multiple myeloma.

Main Methods:

• Literature review of melphalan-based therapies for multiple myeloma.
• Analysis of treatment intensification strategies and stem cell support.
• Overview of novel agents including angiogenesis inhibitors, proteasome inhibitors, and immunotherapy.

Main Results:

• High-dose melphalan with autologous stem cell support is a standard of care for eligible multiple myeloma patients.
• Further intensification strategies like tandem transplantation are under investigation.
• Novel agents demonstrate promising direct and immunomodulatory effects on plasma cells.

Conclusions:

• High-dose melphalan remains a cornerstone of multiple myeloma therapy, with stem cell support crucial for safety.
• The landscape of multiple myeloma treatment is expanding with innovative therapies targeting different pathways.
• Future research directions include optimizing existing regimens and integrating novel agents for enhanced patient survival and quality of life.